Bellerophon Therapeutics WKN: A2PZZR ISIN: US0787713009 Kürzel: BLPH Forum: Aktien Thema: Hauptdiskussion

Und Biontech Inovio Novavax Moderna Alpha Pro Tech etc sind alles Covid Aktien?

Siehe bütz aussagen oben

Weil bello eig keine covid aktie ist!

Hallo zusammen. Alle Covid Aktien fallen gerade. Warum soll Bello davon nicht betroffen sein?

http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-appoints-cardiopulmonary-disease-expert-wassim-fares

🚀🚀🚀

Nochmal ne neue Nachricht: „I look forward to supporting the Company in further advancing the ongoing COVID-19 COViNOX Phase 3 trial and initiating the Phase 3 REBUILD study in PH-PF.”

Bald 🚀🚀🚀

Cool!

Bewerten halt nur den Base Case. Wären 60 Upside. Von mir aus gerne....

https://thefly.com/landingPageNews.php?id=3071453&headline=BLPH-Bellerophon-jumps-after-Brookline-starts-with-Buy-rating--target 19 usd ohne den covid trial. Geil oder....

Bütz was sagst du zu der einschätzung von jeffries? Schau dir mal die news an bitte

PS ich finde langfristig minimiert sich das risiko, nitric oxide = wachsender markt, bello ist vorne dabei, mit mickriger Marktkapitalisierung

Kursziele sehen ja nicht so übel aus. Entscheidend ist meiner Meinung nach eine Partnerschaft oder eine staatliche Unterstützung Als Ergänzung. As of June 30, 2020, the Company had cash and cash equivalents of $59.3 million, compared to $9.9 million at December 31, 2019. Cash ist vorhanden im Vergleich zum Vorjahr. Ich schließe somit eine erneute Kapitalerhöhung aus. Studiendaten sind hervorragend, ich frage mich, was auf uns zu kommt

Kursziele somit erstmal klar

(5) Common Stock Warrants and Warrant Liability On November 29, 2016, the Company issued 1,142,838 warrants that were immediately exercisable and will expire 5 years from issuance at an exercise price of $12.00 per share (the “2016 Warrants”). On June 28, 2019, the Company entered into a warrant amendment (the “Warrant Amendment”) with certain holders (the “Holders”) of 839,899 of the 2016 Warrants to purchase shares. Pursuant to the Warrant Amendment, the Company and the Holders agreed to eliminate provisions that had previously precluded equity classification treatment on the Company’s consolidated balance sheets. In consideration of such amendment, the 2016 Warrants were extended by two (2) additional years (until November 29, 2023). The difference in fair market value of the warrants before and after the amendment, of $0.7 million, was recorded in the consolidated statement of operations as a warrant amendment charge. The fair market value of the amended warrants was reclassified from common stock warrant liability to stockholders' equity. The balance of the 2016 Warrants that were not amended could require cash settlement under certain circumstances, and therefore continue to be classified as liabilities and to be recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of June 30, 2020, 661,310 of the 2016 Warrants were outstanding, of which 585,139 were equity classified and 76,171 were liability classified. During the six months ended June 30, 2020, 254,760 of the 2016 warrants were exercised for net proceeds of $3.1 million.      On May 15, 2017, the Company issued to an investor a warrant to purchase 66,666 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $22.50 per share. In addition, the Company issued to the placement agent warrants to purchase 4,000 shares that were immediately exercisable and will expire five years from issuance at an exercise price of $28.125 per share. As the warrants, under certain situations, could require cash settlement, the warrants were classified as liabilities and recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of June 30, 2020, all of these warrants were outstanding. On September 29, 2017, the Company issued warrants to purchase 1,296,650 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $18.63 per share. As the warrants could not require cash settlement, the warrants were classified as equity. As of June 30, 2020, all of these warrants were outstanding.